ArticleNature reviews. Neurology2025
Advancing multiple sclerosis management in older adults.
Article in Nature reviews. Neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Randomized controlled trial of a remotely-delivered exercise training program in older adults with multiple sclerosis: Secondary effects on cognition, symptoms, and quality of life.Multiple sclerosis and related disorders · 2026Trial
- Risk of infection in ocrelizumab-treated adults with multiple sclerosis aged 55 years and older: a retrospective cohort study.Lancet regional health. Americas · 2026Article
- Polypharmacy, Potential Drug-Drug Interactions and Medication Non-Adherence in Patients with Multiple Sclerosis: A Longitudinal Study.Neurology and therapy · 2026Article
- Evaluating the neurofilament light chain-derived gap between biological and chronological age in multiple sclerosis and controls.Journal of neurology · 2026Article
- Spider-MS: an individualized polyhedral prediction of multiple sclerosis prognosis.Brain : a journal of neurology · 2026Article
- A Delicate Balance: Immunotherapy for Endometrial Cancer in a Patient With Multiple Sclerosis.Journal of medical cases · 2026Article
- Rethinking prognosis in multiple sclerosis: a multiaxial perspective.Nature reviews. Neurology · 2026Review
- Clinical characteristics of late-onset adult autoimmune glial fibrillary acidic protein astrocytopathy: a retrospective cohort study.Journal of neurology · 2026Article
- Structural MRI signature of late- versus adult-onset multiple sclerosis: a multiparametric study.Journal of neurology · 2026Article
- Managing Relapsing Multiple Sclerosis Across the Lifespan: A Narrative Review with Expert Opinion from Norway.Neurology and therapy · 2026Review
- A CSF disease-associated macrophage signature defines progressive multiple sclerosis.Journal of neuroinflammation · 2026Article
- Menopause is a physiological progression event for women with multiple sclerosis: No.Multiple sclerosis (Houndmills, Basingstoke, England) · 2026Article
- Anti-aging and Anti-inflammatory Dietary Interventions in Multiple Sclerosis: A Narrative Review.Neurology and therapy · 2026Review
- The Burden of Multiple Sclerosis in Japan from 1990 to 2021 and Predictions to 2050 Based on the Global Burden of Disease Study 2021.Neuroepidemiology · 2026Article
- Investigating the treatment of vascular risk with simvastatin in secondary progressive multiple sclerosis: analysis from the MS-STAT2 randomized controlled trial.Brain communications · 2026Article
- Clinical, functional and cognitive features of late-onset multiple sclerosis.Journal of neurology · 2025Article
- Global, regional, and national burden of autoimmune disease in older adults (≥60 years) from 1990 to 2021: Results from the Global Burden of Disease Study 2021.The journal of nutrition, health & aging · 2025Article
- Clinical Picture and Outcomes in Patients Diagnosed with Brain Abscess.Journal of clinical medicine · 2025Article
- Safety and efficacy of B-cell therapy in older people with multiple sclerosis.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple sclerosis (MS) typically presents in early to middle adulthood, but owing to advancements in health care, many individuals with MS now live a normal lifespan, and approximately half of the people currently living with MS are ≥50 years of age. As people living with MS age, their diagnosis, treatment and disease management become more complex owing to the effects of ageing, immunosenescence and comorbidities. Furthermore, diagnosis of late-onset MS (onset above 50 years of age) often requires additional tests, such as spinal cord imaging and cerebrospinal fluid analysis, to differentiate the disease from age-associated conditions such as cerebrovascular disease. Monitoring disease progression also becomes more complicated with increasing age, as physiological age-related changes can confound MRI findings and measurements of disability and cognition. Treatment decisions in older people with MS are also challenging, as high-efficacy treatments carry increased risks with ageing and their benefits can be reduced, yet little evidence is available to guide treatment in older adults. In this Consensus statement, we present the outcomes of an International Advisory Committee on Clinical Trials (IACCT) in MS workshop on ageing and MS; we review the current status of the field and identify knowledge gaps, and provide recommendations to advance the areas of unmet need.
Indexed as
Identifiers
40702382What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.